Year: 2020
Language: English
Author(s): World Federation of Hemophilia
Format: Video
The currently evolving novel therapies for the management of hemophilia has ushered in a new era characterized by improved prophylaxis targets and outcomes.
In this session from the WFH 2020 Virtual Summit, Johnny Mahlangu, Victor Blanchette, Robert Klamroth and Emna Gouider redefine prophylaxis in the modern era by revisiting its definition, presenting data to support higher trough levels to achieve through prophylaxis, and introducing steady-state hemostasis as a possible new target for prophylaxis. The benefits of low-dose prophylaxis will also be discussed.
Click on the icon below to access more on-demand Virtual Summit recordings.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.
The currently evolving novel therapies for the management of hemophilia has ushered in a new era characterized by improved prophylaxis
The 2021 edition is available in: English, Spanish, French, Arabic, Russian, Simplified Chinese This resource has also been translated into the
En constante évolution, les nouvelles thérapies pour la prise en charge de l’hémophilie ont inauguré une nouvelle ère caractérisée par
The currently evolving novel therapies for the management of hemophilia has ushered in a new era characterized by improved prophylaxis
Las terapias innovadoras en desarrollo para el tratamiento de la hemofilia han marcado el comienzo de una nueva era caracterizada
In the Tuesday afternoon session entitled Prophylaxis: Global Models of Low-Dose Prophylaxis, Shashikant Apte presents the results of the implementation